Assembly Biosciences (ASMB) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

ASMB Stock Forecast

Assembly Biosciences stock forecast is as follows: an average price target of $35.50 (represents a 119.95% upside from ASMB’s last price of $16.14) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

ASMB Price Target

The average price target for Assembly Biosciences (ASMB) is $35.50 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $36.00 to $35.00. This represents a potential 119.95% upside from ASMB's last price of $16.14.

ASMB Analyst Ratings

Buy

According to 2 Wall Street analysts, Assembly Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for ASMB stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Assembly Biosciences Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Sep 24, 2024	Salim Syed	Mizuho Securities	$36.00	$16.26	121.40%	123.05%
Sep 20, 2024	Dennis Ding	Jefferies	$35.00	$18.50	89.19%	116.85%

Row per page

Go to

The latest Assembly Biosciences stock forecast, released on Sep 24, 2024 by Salim Syed from Mizuho Securities, set a price target of $36.00, which represents a 121.40% increase from the stock price at the time of the forecast ($16.26), and a 123.05% increase from ASMB last price ($16.14).

Assembly Biosciences Price Target by Period

	1M	3M	12M
# Anlaysts	-	2	2
Avg Price Target	-	$35.50	$35.50
Last Closing Price	$16.14	$16.14	$16.14
Upside/Downside	-100.00%	119.95%	119.95%

In the current month, the average price target of Assembly Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Assembly Biosciences's last price of $16.14. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 24, 2024	H.C. Wainwright	Neutral	Neutral	Hold
Sep 20, 2024	Jefferies	-	Buy	Upgrade

Row per page

Go to

Assembly Biosciences's last stock rating was published by H.C. Wainwright on Sep 24, 2024. The company gave ASMB a "Neutral" rating, the same as its previous rate.

Assembly Biosciences Financial Forecast

Assembly Biosciences Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.04M	$34.61M	$39.38M	$4.08M	$4.77M	$4.23M	$3.08M	$3.88M	$3.57M	$684.37K
Avg Forecast	$3.80M	$4.06M	$4.00M	$8.50M	$8.60M	$8.40M	$8.15M	$7.95M	$5.20M	$5.77M	$6.00M	$1.56M	$1.63M	$2.51M	$3.97M	$6.44M	$30.54M	$3.82M	$3.73M	$3.44M	$3.65M	$3.21M	$3.39M	$25.18K
High Forecast	$4.02M	$4.29M	$4.23M	$8.99M	$9.10M	$8.89M	$8.62M	$8.48M	$5.68M	$6.10M	$6.35M	$1.56M	$1.63M	$2.51M	$3.97M	$6.44M	$30.54M	$3.82M	$3.73M	$3.44M	$3.65M	$3.21M	$4.07M	$30.22K
Low Forecast	$3.58M	$3.82M	$3.77M	$8.01M	$8.10M	$7.91M	$7.68M	$7.42M	$4.71M	$5.43M	$5.65M	$1.56M	$1.63M	$2.51M	$3.97M	$6.44M	$30.54M	$3.82M	$3.73M	$3.44M	$3.65M	$3.21M	$2.71M	$20.15K
# Analysts	1	1	1	1	1	1	1	2	1	1	1	1	1	7	5	5	9	6	4	4	7	4	11	10
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.26%	5.38%	1.29%	1.07%	1.28%	1.23%	0.84%	1.21%	1.05%	27.17%

Assembly Biosciences's average Quarter revenue forecast for Mar 21 based on 7 analysts is $2.51M, with a low forecast of $2.51M, and a high forecast of $2.51M. ASMB's average Quarter revenue forecast represents a 141.67% increase compared to the company's last Quarter revenue of $1.04M (Dec 20).

Assembly Biosciences EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	1	1	1	2	1	1	1	1	1	7	5	5	9	6	4	4	7	4	11	10
EBITDA	-	-	-	-	-	-	-	-	-	-	-	$-62.79M	$-23.48M	$-27.09M	$-39.10M	$-3.21M	$7.39M	$-26.54M	$-27.71M	$-24.89M	$-18.39M	$-26.92M	$-16.08M	$-13.90M
Avg Forecast	$-2.14M	$-2.29M	$-2.26M	$-4.79M	$-4.85M	$-4.74M	$-4.59M	$-4.48M	$-2.93M	$-3.25M	$-3.38M	$-878.73K	$-913.29K	$-30.59M	$-2.23M	$-3.62M	$-17.17M	$-32.50M	$-2.10M	$-1.94M	$-2.05M	$-26.67M	$-15.23M	$-312.72M
High Forecast	$-2.02M	$-2.15M	$-2.12M	$-4.51M	$-4.57M	$-4.46M	$-4.33M	$-4.18M	$-2.66M	$-3.06M	$-3.19M	$-878.73K	$-913.29K	$-24.47M	$-2.23M	$-3.62M	$-17.17M	$-26.00M	$-2.10M	$-1.94M	$-2.05M	$-21.33M	$-12.19M	$-250.18M
Low Forecast	$-2.27M	$-2.42M	$-2.39M	$-5.07M	$-5.13M	$-5.01M	$-4.86M	$-4.78M	$-3.20M	$-3.44M	$-3.58M	$-878.73K	$-913.29K	$-36.71M	$-2.23M	$-3.62M	$-17.17M	$-39.00M	$-2.10M	$-1.94M	$-2.05M	$-32.00M	$-18.28M	$-375.26M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	71.45%	25.70%	0.89%	17.52%	0.89%	-0.43%	0.82%	13.21%	12.86%	8.97%	1.01%	1.06%	0.04%

5 analysts predict ASMB's average Quarter EBITDA for Sep 20 to be $-3.62M, with a high of $-3.62M and a low of $-3.62M. This is -148.93% lower than Assembly Biosciences's previous annual EBITDA (Jun 20) of $7.39M.

Assembly Biosciences Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	1	1	1	2	1	1	1	1	1	7	5	5	9	6	4	4	7	4	11	10
Net Income	-	-	-	-	-	-	-	-	-	-	-	$-60.26M	$-23.59M	$-27.20M	$-39.42M	$-3.35M	$7.27M	$-26.66M	$-27.08M	$-25.00M	$-18.50M	$-27.05M	$-16.25M	$-13.93M
Avg Forecast	$-15.91M	$-15.63M	$-13.15M	$-10.27M	$-10.50M	$-10.50M	$-10.33M	$-12.47M	$-11.40M	$-13.00M	$-12.58M	$-32.91M	$-44.69M	$-30.64M	$-59.47M	$-50.78M	$-2.03M	$-32.64M	$-68.22M	$-62.97M	$-76.52M	$-26.79M	$-15.39M	$-313.44M
High Forecast	$-14.71M	$-14.45M	$-12.15M	$-9.49M	$-9.70M	$-9.70M	$-9.54M	$-11.00M	$-9.78M	$-12.01M	$-11.63M	$-32.91M	$-44.69M	$-24.51M	$-59.47M	$-50.78M	$-2.03M	$-26.11M	$-68.22M	$-62.97M	$-76.52M	$-21.43M	$-12.31M	$-250.75M
Low Forecast	$-17.11M	$-16.81M	$-14.14M	$-11.04M	$-11.29M	$-11.29M	$-11.10M	$-13.94M	$-13.02M	$-13.98M	$-13.53M	$-32.91M	$-44.69M	$-36.77M	$-59.47M	$-50.78M	$-2.03M	$-39.17M	$-68.22M	$-62.97M	$-76.52M	$-32.15M	$-18.47M	$-376.13M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	1.83%	0.53%	0.89%	0.66%	0.07%	-3.58%	0.82%	0.40%	0.40%	0.24%	1.01%	1.06%	0.04%

Assembly Biosciences's average Quarter net income forecast for Sep 20 is $-50.78M, with a range of $-50.78M to $-50.78M. ASMB's average Quarter net income forecast represents a -798.55% decrease compared to the company's last Quarter net income of $7.27M (Jun 20).

Assembly Biosciences SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	1	1	1	2	1	1	1	1	1	7	5	5	9	6	4	4	7	4	11	10
SG&A	-	-	-	-	-	-	-	-	-	-	-	$6.50M	$6.92M	$8.70M	$7.17M	$11.69M	$9.47M	$8.73M	$10.83M	$8.49M	$4.08M	$9.52M	$5.70M	$4.04M
Avg Forecast	$8.61M	$9.19M	$9.06M	$19.26M	$19.49M	$19.04M	$18.47M	$18.02M	$11.78M	$13.07M	$13.60M	$3.52M	$3.66M	$5.65M	$8.95M	$14.50M	$68.83M	$8.60M	$8.41M	$7.76M	$8.22M	$7.22M	$7.64M	$56.76K
High Forecast	$9.11M	$9.72M	$9.59M	$20.38M	$20.62M	$20.14M	$19.54M	$19.21M	$12.87M	$13.82M	$14.38M	$3.52M	$3.66M	$5.65M	$8.95M	$14.50M	$68.83M	$8.60M	$8.41M	$7.76M	$8.22M	$7.22M	$9.17M	$68.11K
Low Forecast	$8.11M	$8.66M	$8.54M	$18.14M	$18.35M	$17.93M	$17.39M	$16.82M	$10.68M	$12.31M	$12.81M	$3.52M	$3.66M	$5.65M	$8.95M	$14.50M	$68.83M	$8.60M	$8.41M	$7.76M	$8.22M	$7.22M	$6.11M	$45.40K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	1.85%	1.89%	1.54%	0.80%	0.81%	0.14%	1.01%	1.29%	1.09%	0.50%	1.32%	0.75%	71.19%

Assembly Biosciences's average Quarter SG&A projection for Jun 24 is $13.60M, based on 1 Wall Street analysts, with a range of $12.81M to $14.38M. The forecast indicates a 109.05% rise compared to ASMB last annual SG&A of $6.50M (Dec 21).

Assembly Biosciences EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	1	1	1	2	1	1	1	1	1	7	5	5	9	6	4	4	7	4	11	10
EPS	-	-	-	-	-	-	-	-	-	-	-	$-1.32	$-0.55	$-0.69	$-0.99	$-0.09	$0.21	$-0.76	$-0.77	$-0.96	$-0.72	$-1.05	$-0.80	$-0.81
Avg Forecast	$-2.82	$-2.77	$-2.33	$-1.82	$-1.86	$-1.86	$-1.83	$-2.21	$-2.02	$-2.30	$-2.23	$-5.83	$-7.92	$-9.26	$-10.54	$-9.00	$-0.36	$-11.73	$-12.09	$-11.16	$-13.56	$-12.76	$-0.72	$-0.68
High Forecast	$-2.61	$-2.56	$-2.15	$-1.68	$-1.72	$-1.72	$-1.69	$-1.95	$-1.73	$-2.13	$-2.06	$-5.83	$-7.92	$-9.26	$-10.54	$-9.00	$-0.36	$-11.73	$-12.09	$-11.16	$-13.56	$-12.76	$-0.58	$-0.54
Low Forecast	$-3.03	$-2.98	$-2.51	$-1.96	$-2.00	$-2.00	$-1.97	$-2.47	$-2.31	$-2.48	$-2.40	$-5.83	$-7.92	$-9.26	$-10.54	$-9.00	$-0.36	$-11.73	$-12.09	$-11.16	$-13.56	$-12.76	$-0.86	$-0.81
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.23%	0.07%	0.07%	0.09%	0.01%	-0.58%	0.06%	0.06%	0.09%	0.05%	0.08%	1.11%	1.19%

According to 5 Wall Street analysts, Assembly Biosciences's projected average Quarter EPS for Sep 20 is $-9.00, with a low estimate of $-9.00 and a high estimate of $-9.00. This represents a -4385.71% decrease compared to ASMB previous annual EPS of $0.21 (Jun 20).

Assembly Biosciences Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
SPRO	Spero Therapeutics	$1.18	$10.00	747.46%	Buy
CTMX	CytomX Therapeutics	$0.91	$5.73	529.67%	Buy
TIL	Instil Bio	$26.50	$78.25	195.28%	Hold
NUVB	Nuvation Bio	$2.63	$6.75	156.65%	Buy
NXTC	NextCure	$1.31	$3.00	129.01%	Buy
ASMB	Assembly Biosciences	$16.14	$35.50	119.95%	Buy
ACHL	Achilles Therapeutics	$1.05	$2.00	90.48%	Buy

ASMB Forecast FAQ

Is Assembly Biosciences a good buy?

Yes, according to 2 Wall Street analysts, Assembly Biosciences (ASMB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of ASMB's total ratings.

What is ASMB's price target?

Assembly Biosciences (ASMB) average price target is $35.5 with a range of $35 to $36, implying a 119.95% from its last price of $16.14. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Assembly Biosciences stock go up soon?

According to Wall Street analysts' prediction for ASMB stock, the company can go up by 119.95% (from the last price of $16.14 to the average price target of $35.5), up by 123.05% based on the highest stock price target, and up by 116.85% based on the lowest stock price target.

Can Assembly Biosciences stock reach $20?

ASMB's average twelve months analyst stock price target of $35.5 supports the claim that Assembly Biosciences can reach $20 in the near future.

What are Assembly Biosciences's analysts' financial forecasts?

Assembly Biosciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $33.1M (high $35.08M, low $31.11M), average EBITDA is $-18.661M (high $-17.537M, low $-19.78M), average net income is $-43.788M (high $-39.951M, low $-47.611M), average SG&A $75.01M (high $79.51M, low $70.49M), and average EPS is $-7.76 (high $-7.08, low $-8.438). ASMB's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $20.36M (high $21.53M, low $19.17M), average EBITDA is $-11.476M (high $-10.808M, low $-12.14M), average net income is $-54.96M (high $-50.802M, low $-59.096M), average SG&A $46.13M (high $48.8M, low $43.44M), and average EPS is $-9.74 (high $-9.003, low $-10.473).

Did the ASMB's actual financial results beat the analysts' financial forecasts?

Based on Assembly Biosciences's last annual report (Dec 2021), the company's revenue was $6.25M, beating the average analysts forecast of $5.69M by 9.82%. Apple's EBITDA was $-49.412M, beating the average prediction of $-32.38M by 52.60%. The company's net income was $-130M, beating the average estimation of $-108M by 19.97%. Apple's SG&A was $28.78M, beating the average forecast of $12.83M by 124.26%. Lastly, the company's EPS was $-3, missing the average prediction of $-23.012 by -86.96%. In terms of the last quarterly report (Dec 2020), Assembly Biosciences's revenue was $1.04M, missing the average analysts' forecast of $3.97M by -73.88%. The company's EBITDA was $-39.104M, beating the average prediction of $-2.232M by 1652.20%. Assembly Biosciences's net income was $-39.418M, missing the average estimation of $-59.475M by -33.72%. The company's SG&A was $7.17M, missing the average forecast of $8.95M by -19.88%. Lastly, the company's EPS was $-0.993, missing the average prediction of $-10.54 by -90.57%